WHO’s Emergency Use Listing (EUL) is a prerequisite for a vaccine to become a part of the Covax facility’s vaccine supply and international procurement scheme. It also allows countries to expedite their regulatory approval to import and administer COVID-19 vaccines.
The Sinovac-CoronaVac product is an inactivated vaccine. Its easy storage requirements make it very manageable and particularly suitable for low-resource settings, a statement from WHO said.
WHO’s Strategic Advisory Group of Experts on Immunisation (SAGE) has also completed its review of the vaccine.
Vaccine efficacy results showed that the vaccine prevented symptomatic disease in 51 per cent of those vaccinated and prevented severe COVID-19 and hospitalisation in 100 percent of the studied population.
According to AFP, the Sinovac vaccine is already in use in 22 places around the world.
WHO has also granted emergency use listing to the Pfizer-BioNTech, Moderna, Johnson & Johnson vaccines, as well as the AstraZeneca jab being produced in India, South Korea and the EU.
(With inputs from AFP.)
(The Quint is available on Telegram. For handpicked stories every day, subscribe to us on Telegram)
Crime Today News | INDIA